Search research articles
Contact Us
Filters
Showing results (291-300 of 429) with videos related to
Page
of 43
Sort By:
Leukemia & Lymphoma
|
June 29, 2010
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
Ajay K Gopal, Oliver W Press, Andrei R Shustov, et al.
Cancer Causes & Control : CCC
|
January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access intervention
Kristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
British Journal of Haematology
|
January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma
Andrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
Roland B Walter, Ted A Gooley, Brent L Wood, et al.
Blood
|
June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
Damian J Green, John M Pagel, Eneida R Nemecek, et al.
Leukemia & Lymphoma
|
August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies
Andres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
Solomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
JCO Oncology Practice
|
November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience
Ivan J Huang, Grace T Baek, Jonathan Cohen, et al.
Bone Marrow Transplantation
|
July 1, 2026
Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis
Ivan J Huang, Grace T Baek, Qian Vicky Wu, et al.
Page
of 43
Search research articles
Search
Showing results (291-300 of 429) with videos related to
Sort By:
Page
of 43
Leukemia & Lymphoma
|
June 29, 2010
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
Ajay K Gopal, Oliver W Press, Andrei R Shustov, et al.
Cancer Causes & Control : CCC
|
January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access intervention
Kristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
British Journal of Haematology
|
January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma
Andrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia
Roland B Walter, Ted A Gooley, Brent L Wood, et al.
Blood
|
June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
Damian J Green, John M Pagel, Eneida R Nemecek, et al.
Leukemia & Lymphoma
|
August 12, 2014
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies
Andres Forero-Torres, Nancy L Bartlett, Robert B Berryman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 28, 2020
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
Solomon A Graf, Ryan D Cassaday, Karolyn Morris, et al.
Journal of the National Cancer Institute
|
January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E Spurgeon, Brian G Till, Peter Martin, et al.
JCO Oncology Practice
|
November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience
Ivan J Huang, Grace T Baek, Jonathan Cohen, et al.
Bone Marrow Transplantation
|
July 1, 2026
Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis
Ivan J Huang, Grace T Baek, Qian Vicky Wu, et al.
Page
of 43